Search results
Showing 6316 to 6330 of 8917 results
Hidden spine fractures could be spotted earlier after NICE recommendation
NICE is recommending that quick spine checks are added to routine bone scans to help spot hidden fractures earlier and prevent serious complications.
Digital platforms recommended to help people manage their asthma
People with asthma could benefit from digital tools on their phones or tablets to help them better manage their condition, states our draft guidance published today.
New sepsis guideline targets faster, tailored treatments to benefit patients
Patients aged 16 or over with suspected sepsis will receive more tailored treatment under updated NICE guidance published today.
New age-based blood test thresholds recommended by NICE will help GPs catch ovarian cancer earlier
More women with ovarian cancer could be diagnosed earlier under proposed new NICE guidance that replaces a one-size-fits-all blood test threshold with personalised, age-based criteria.
Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma [ID1470]
Discontinued Reference number: GID-TA10354
Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466]
Discontinued Reference number: GID-TA10355
Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies [ID1455]
Discontinued Reference number: GID-TA10356
Nintedanib for untreated malignant pleural mesothelioma [ID1424]
Discontinued Reference number: GID-TA10359
Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]
Discontinued Reference number: GID-TA10363
Discontinued Reference number: GID-TA10365
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]
Discontinued Reference number: GID-TA10377
Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]
Discontinued Reference number: GID-TA10380
Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma [ID997]
Discontinued Reference number: GID-TA10382
Discontinued Reference number: GID-TA10390
In development Reference number: GID-TA10391 Expected publication date: TBC